Many patients, most notably women and diabetics, are more likely to show atypical signs of a heart attack. These could range from toothache to backache.
Inc. today provided full-year Abecma® (idecabtagene vicleucel; ide-cel) sales results for 2024, in partnership with Bristol Myers Squibb (BMS). "We are pleased to see Abecma expansion in the third ...